France

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of 14 new devices and for the extension of indications for three devices. Opinions concerned multiple fields, including cardiovascular, diagnostic imaging, ENT, e-health, endocrine, interventional radiology, nephrology, neuromodulation, orthopedics, spine, peripheral vascular, and pulmonology.

On April 16, 2026, the French Ministry of Health announced the inclusion of the first in vitro diagnostic medical device under the reformed RIHN 2.0, designed to support innovative diagnostics through temporary reimbursement while evidence is generated. The selected technology is VisioCyt Bladder, an AI-assisted digital urine cytology, indicated for monitoring recurrence in non-muscle-invasive bladder cancer. This marks a key milestone in the implementation of the updated framework.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the March 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favorable opinion was issued on the add-on reimbursement for three new devices in the gastrointestinal endoscopy, men’s health, and orthopedics fields.

In February 2026, the French Ministry of Health, Family, Autonomy, and People with Disabilities announced three new experiments under Article 51 of the Social Security Financing Act. They relate to nephrology and neuro-orthopedics, and to the provision of care to discharged, dependent, elderly individuals experiencing loss of autonomy or chronic illness.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the February 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favourable opinions were issued on the add-on reimbursement for six new devices and on the extension of indications for two devices, in the cardiovascular, peripheral vascular, and ENT fields.

A new version of the Nomenclature of Medical Biology Procedures (NABM 102), effective from March 3, 2026, was published in France. Changes include the introduction of one new code and the deletion and modification of several codes.

On February 7, 2026, the Ministry of Health, Family, Autonomy and People with Disability released an update of the 2014 regulations on conditions of performing IVD tests outside the medical biology laboratory. The new regulation expands the list of locations eligible for point-of-care testing (POCT) and provides an explicit list of tests that can be performed as POCT, and links them to eligible locations. It also introduces a quality assurance framework, accreditation requirements, and mandates that comprehensive conventions be concluded between the remote sites providing POCT and the responsible laboratories.

In early February 2026, the French National Authority for Health (HAS) opened the call for applications for the evaluation of medical procedures and in-vitro diagnostic (IVD) tests to be included in its 2027 working program. The deadline for submission is May 4, 2026.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the January 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favourable opinion was issued on the add-on reimbursement for one new device, as well as on the extension of indications for two devices for transcatheter aortic valve implantation.

On January 13, 2026, a new version of the Nomenclature of Medical Biology Procedures (NABM 101) was published in France. A new chapter for constitutional genetics was introduced, including two new codes.

On January 14, 2026, the French Ministry of Health, Family, Autonomy and People with Disability published the Order setting DRG tariffs and tariffs for other packages and supplements for 2026. The released tariffs are in effect from January 1, 2026, and include new, higher DRG tariffs for several procedures, such as HIFU destruction of prostate lesions, as well as updates to packages for organ perfusion technologies for transplantation.

On January 1, 2026, the specifications of the call for projects "Support for disruptive innovations in the implantable medical devices and surgical robotics sector" were approved. This initiative, part of the France 2030 investment plan, aims to support research and development projects targeting implantable medical devices and next-generation surgical robots.